history of glp-1 drugs Glucagon-like peptide-1 analogs: Miracle are blooming? Discovery of GLP-1–Based Drugs for
Description
Phase 2b IMPACT completed for MASH
A brief mechanistic summary of potential pathways targeted by GLP-1s in relation to CVD is provided in Fig
(13) Disruption of this balancesuch as elevated RANKL or reduced OPGis linked to increased bone resorption and delayed fracture healing, particularly in diabetes
Yao et al
The combination of GIP and glucagon receptor activation appears to produce additive benefits for liver fat reduction and metabolic health that neither receptor achieves alone
